IBDEI10O ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16535,2)
 ;;=^5001108
 ;;^UTILITY(U,$J,358.3,16536,0)
 ;;=C22.0^^61^775^104
 ;;^UTILITY(U,$J,358.3,16536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16536,1,3,0)
 ;;=3^Liver Cell Carcinoma
 ;;^UTILITY(U,$J,358.3,16536,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,16536,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,16537,0)
 ;;=D05.02^^61^775^105
 ;;^UTILITY(U,$J,358.3,16537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16537,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,16537,1,4,0)
 ;;=4^D05.02
 ;;^UTILITY(U,$J,358.3,16537,2)
 ;;=^5001928
 ;;^UTILITY(U,$J,358.3,16538,0)
 ;;=D05.01^^61^775^106
 ;;^UTILITY(U,$J,358.3,16538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16538,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,16538,1,4,0)
 ;;=4^D05.01
 ;;^UTILITY(U,$J,358.3,16538,2)
 ;;=^5001927
 ;;^UTILITY(U,$J,358.3,16539,0)
 ;;=D05.00^^61^775^107
 ;;^UTILITY(U,$J,358.3,16539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16539,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,16539,1,4,0)
 ;;=4^D05.00
 ;;^UTILITY(U,$J,358.3,16539,2)
 ;;=^5001926
 ;;^UTILITY(U,$J,358.3,16540,0)
 ;;=R59.0^^61^775^66
 ;;^UTILITY(U,$J,358.3,16540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16540,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Localized
 ;;^UTILITY(U,$J,358.3,16540,1,4,0)
 ;;=4^R59.0
 ;;^UTILITY(U,$J,358.3,16540,2)
 ;;=^5019529
 ;;^UTILITY(U,$J,358.3,16541,0)
 ;;=C83.59^^61^775^108
 ;;^UTILITY(U,$J,358.3,16541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16541,1,3,0)
 ;;=3^Lymphoblastic Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,16541,1,4,0)
 ;;=4^C83.59
 ;;^UTILITY(U,$J,358.3,16541,2)
 ;;=^5001590
 ;;^UTILITY(U,$J,358.3,16542,0)
 ;;=C83.50^^61^775^109
 ;;^UTILITY(U,$J,358.3,16542,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16542,1,3,0)
 ;;=3^Lymphoblastic Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,16542,1,4,0)
 ;;=4^C83.50
 ;;^UTILITY(U,$J,358.3,16542,2)
 ;;=^5001581
 ;;^UTILITY(U,$J,358.3,16543,0)
 ;;=C43.9^^61^775^112
 ;;^UTILITY(U,$J,358.3,16543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16543,1,3,0)
 ;;=3^Malig Melanoma of Skin,Unspec Site
 ;;^UTILITY(U,$J,358.3,16543,1,4,0)
 ;;=4^C43.9
 ;;^UTILITY(U,$J,358.3,16543,2)
 ;;=^5001015
 ;;^UTILITY(U,$J,358.3,16544,0)
 ;;=C31.9^^61^775^113
 ;;^UTILITY(U,$J,358.3,16544,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16544,1,3,0)
 ;;=3^Malig Neop Accessory Sinus,Unspec
 ;;^UTILITY(U,$J,358.3,16544,1,4,0)
 ;;=4^C31.9
 ;;^UTILITY(U,$J,358.3,16544,2)
 ;;=^5000953
 ;;^UTILITY(U,$J,358.3,16545,0)
 ;;=C24.1^^61^775^115
 ;;^UTILITY(U,$J,358.3,16545,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16545,1,3,0)
 ;;=3^Malig Neop Ampulla of Vater
 ;;^UTILITY(U,$J,358.3,16545,1,4,0)
 ;;=4^C24.1
 ;;^UTILITY(U,$J,358.3,16545,2)
 ;;=^267100
 ;;^UTILITY(U,$J,358.3,16546,0)
 ;;=C21.0^^61^775^116
 ;;^UTILITY(U,$J,358.3,16546,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16546,1,3,0)
 ;;=3^Malig Neop Anus,Unspec
 ;;^UTILITY(U,$J,358.3,16546,1,4,0)
 ;;=4^C21.0
 ;;^UTILITY(U,$J,358.3,16546,2)
 ;;=^5000930
 ;;^UTILITY(U,$J,358.3,16547,0)
 ;;=C67.9^^61^775^119
 ;;^UTILITY(U,$J,358.3,16547,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16547,1,3,0)
 ;;=3^Malig Neop Bladder,Unspec
 ;;^UTILITY(U,$J,358.3,16547,1,4,0)
 ;;=4^C67.9
 ;;^UTILITY(U,$J,358.3,16547,2)
 ;;=^5001263
 ;;^UTILITY(U,$J,358.3,16548,0)
 ;;=C71.9^^61^775^123
